Endogenous fructose production: what do we know and how relevant is it?
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic pathways and preclinical animal studies with no original clinical data.
PubMed 31166222 · doi:10.1097/MCO.0000000000000573
What was done
This narrative review synthesized recent findings on the activation of the polyol pathway, endogenous fructose synthesis from glucose across tissues (liver, renal cortex, hypothalamus), and the effects of fructokinase blockade in animal models of metabolic and renal disease.
What was found
The abstract reports no numerical data. It notes qualitatively that stimuli such as osmotic stress, diabetes, and ischemia activate the polyol pathway, and that blocking endogenous fructose metabolism via fructokinase-deficient mice or specific inhibitors markedly ameliorated metabolic diseases.
Why it matters
It highlights that fructose-induced pathology may originate from internal glucose conversion via the polyol pathway as well as dietary intake, suggesting fructokinase inhibition as a potential therapeutic target.
Limits
The abstract describes preclinical mechanism-based animal models rather than human clinical trials. No quantitative metrics, search methods, or sample sizes are reported in the abstract.
Cited by
- supports Only a small amount of dietary fructose enters the brain, but consumption of sugar, salt, and high-glycemic carbohydrates stimulates endogenous fructose production in the brain.